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Tuberculosis (TB) remains a global health threat. 
Despite a slow decline in global TB rates, the World 
Health Organization (WHO) reported 8.6 million 
new cases of TB in 2012 (13% in people living with 
HIV), resulting in 1.3 million deaths (23% among 
HIV-positive persons).[1] South Africa (SA) has one of the world’s 
worst TB epidemics driven by HIV. The WHO has identified 
22 high-burden countries (HBCs), which account for 81% of all 
estimated incident TB cases globally. 
Among the HBCs, SA has the third highest absolute number of 
reported incident cases and the fifth highest number of estimated 
prevalent (undiagnosed active TB) cases.[1] After adjusting for 
population size, SA has the highest incidence and prevalence of TB 
among the HBCs. It also has the largest number of HIV-associated 
TB cases and the second-largest number of diagnosed multidrug-
resistant (MDR)-TB cases (after India).[1] 
The National Tuberculosis Programme (NTP), established after SA 
became a democracy in 1994, faced the challenge of integrating TB 
services into weak primary healthcare systems and the emergence of the 
HIV epidemic, which led to TB case rates quadrupling between 1994 and 
2012 (Fig. 1).[2] The growing burden of MDR-TB and the emergence of 
extensively drug-resistant (XDR) TB in 2006 added a further burden to 
overstretched health services. In order to respond to the dual epidemics 
of HIV and TB rationally, SA developed an integrated National Strategic 
Plan (NSP) for HIV, STIs and TB (2012 - 2016).[3] The targets set in the 
NSP for TB are to halve TB incidence and mortality by 2016 and to 
have no new TB infections, deaths or stigma by 2032. In this review we 
highlight successes and challenges in TB prevention, treatment and care 
and discuss strategies to achieve the NSP targets. 
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Tuberculosis (TB) remains a global health threat, and South Africa (SA) has one of the world’s worst TB epidemics driven by HIV. Among 
the 22 countries with the highest burden of TB, SA has the highest estimated incidence and prevalence of TB, the second highest number 
of diagnosed multidrug-resistant TB cases, and the largest number of HIV-associated TB cases. Although SA has made notable progress 
in reducing TB prevalence and deaths and improving treatment outcomes for new smear-positive TB cases, the burden of TB remains 
enormous. SA has the means to overcome this situation. In addition to better implementing the basics of TB diagnosis and treatment, 
scaling up the use of Xpert MTB/RIF as a replacement for sputum smear microscopy, strengthening case finding in and beyond healthcare 
facilities and a greater focus on TB prevention for people living with HIV, particularly earlier initiation of and scaling up antiretroviral 
therapy and scaling up continuous isoniazid preventive therapy, will have a substantial impact on TB control. New TB drugs, diagnostics 
and vaccines are required to further accelerate progress towards improved TB control in SA and beyond. 
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Fig. 1. Trends in tuberculosis case notification rates and HIV prevalence in 
South Africa.
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TB control
The central pillars of TB control include finding, treating and 
preventing TB in order to avoid TB deaths and reduce transmission. 
The NTP has substantially strengthened the TB control programme 
since 1994, and the major milestones are summarised in Table  1. 
Encouragingly, the efforts of the NTP have contributed to a slow 
decline in TB case notification rates since 2009 (Fig. 1). 
Find TB
SA has an extensive network of microscopy centres and diagnostic 
laboratories with the capacity for culture and drug susceptibility 
testing using the Mycobacterial Growth Indicator Tube liquid culture 
system. In 2011, SA introduced Xpert MTB/RIF as a replacement 
for sputum smear microscopy for the diagnosis of pulmonary TB. 
Between March 2011 and April 2013 >1.3 million Xpert MTB/RIF 
tests were done in SA, which accounted for more than half of the 
global usage of Xpert MTB/RIF. SA also pioneered the use of dried 
culture spots for verification and external quality assurance of Xpert 
MTB/RIF[4] and implemented a central data monitoring system to 
remotely monitor the performance of Xpert MTB/RIF, the proportion 
of positive tests and the proportion with rifampicin resistance. 
Although nationwide implementation of Xpert MTB/RIF is almost 
complete, numerous challenges to its implementation remain. Xpert 
is not universally utilised and there has been poor adherence to 
the Xpert algorithm, requiring simplification of the algorithm for 
monitoring treatment response and investigation of HIV-positive, 
Xpert-negative persons with suspected TB. Ensuring an uninterrupted 
supply of cartridges will remain a challenge as the global demand for 
Xpert cartridges increases. The recording and reporting of Xpert 
results remain suboptimal.
Treat TB
SA’s treatment success rate among new smear-positive and smear-
negative/extrapulmonary TB patients has improved to 79% and 76%, 
respectively, achieved largely as a result of an increase in cure rates 
and a decline in the treatment default rate following the introduction 
of community-based tracing teams.[1] The treatment success rate 
among retreatment cases remains poor at 66.3%. Of concern, up to 
25% of sputum smear-positive TB cases are lost to follow-up before 
treatment initiation, which may contribute to ongoing transmission 
and an increased risk of death.[5] Strategies to reduce initial loss to 
follow-up are required. The mortality rate remains high even after 
completion of TB treatment, probably due to HIV disease.[6] Scaling 
up antiretroviral therapy (ART) to all HIV-infected TB patients is 
required to reduce HIV-related mortality among TB patients. 
The national rollout of Xpert MTB/RIF has enabled rapid 
diagnosis of rifampicin resistance. As a result SA is in the process of 
withdrawing the use of streptomycin for retreatment TB: rifampicin-
susceptible retreatment TB cases are treated with a first-line regimen, 
and rifampicin-resistant retreatment cases are managed according to 
MDR-TB guidelines. 
Prevent TB
Prevention of TB has been a neglected aspect of TB control. TB 
prevention strategies include: treatment of latent TB infection among 
high-risk persons; case finding to detect and treat infectious TB 
earlier, reducing the duration of infectiousness and transmission; 
early ART for people living with HIV; and TB vaccination strategies. 
In this regard, SA adopted the ‘3Is’ policy of isoniazid preventive 
therapy (IPT), intensified case finding and infection control in 2002.
TB screening
TB screening of high-risk persons or groups may contribute to 
reduced deaths and TB transmission. The WHO recommends that 
people living with HIV are systematically screened for TB at each 
contact with the heath service, using a symptom screen. In 2012, 
949 800 HIV-positive South Africans were screened for TB, which 
although impressive is still substantially below the total number of 
people living with HIV in care.[1] Among persons on long-term ART, 
Table 1. National Tuberculosis Programme milestones
1997 Phased implementation of DOTS, establishment of DTDs
1999 Introduction of fixed-dose combination drugs 
Establishment of TB and HIV pilot districts
2000 MDR-TB guidelines endorsed, establishment of MDR-TB 
treatment facilities
Four-drug fixed-dose combination tablets introduced
2001 National Drug Resistance Survey
2002 Launch of the MTDP, 2002 - 2005
Guidelines for IPT for TST-positive, HIV-infected persons
2003 TB declared an emergency and TB crisis plan launched
Electronic TB register introduced 
2005 Minister of Health signs ‘Declaration of TB as an 
emergency in AFRO region’
2006 Development of MDR-TB and XDR-TB action plan
2007 Launch of the National TB Strategic Plan 2007 - 2011
Development of infection control guidelines for TB
2008 Introduction of Hain MTBDRplus as a rapid test for 
MDR-TB
First SA TB conference
2009 ‘Health in South Africa’ series published in The Lancet, 
including recommendations for TB/HIV
WHO review of the NTP
2010 6-month IPT for all HIV-infected persons, regardless of 
TST status
ART for TB patients living with HIV with CD4+ counts 
<350 cells/µl
2011 Introduction of Xpert MTB/Rif as a replacement for 
sputum smear microscopy
National HIV/TB campaign 
Management of DR TB policy guidelines approved
Decentralised management of MDR-TB introduced
2012 SA President signs SADC declaration on ‘TB in the mines’
ART for all HIV-infected TB patients
Streptomycin removed from retreatment regimen
2013 NDoH guidelines for managing TB/HIV in prisons issued
IPT for at least 36 months for TST-positive, HIV-infected 
persons
National drug resistance survey
Independent WHO Review of NTP 
DOTS = directly observed therapy, short-course; DTDs = demonstration and training 
districts;  TB = tuberculosis; MDR = multidrug-resistant; MTDP = Medium Term 
Development Plan; IPT = isoniazid preventive therapy; TST = tuberculin skin test;  
AFRO = World Health Organization Regional Office for Africa; XDR = extensively 
drug-resistant; SA = South African; WHO = World Health Organization; NTP = National 
Tuberculosis Programme; ART = antiretroviral therapy; DR = drug-resistant;  
SADC = Southern African Development Community; NDoH = National Department 
of Health.
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the prevalence of undiagnosed TB remains high, and underscores the 
need for ongoing TB screening.[7,8] TB screening should be scaled up 
to achieve high coverage to ensure that HIV-infected persons with TB 
are diagnosed and treated appropriately. 
SA introduced a multifaceted TB screening programme in 
2011, focused on high-burden districts, which included household 
contact tracing, HIV counselling and testing campaigns, community 
mobilisation, door-to-door enquiry in areas with a high burden of 
smear-positive TB, and screening of high-risk populations. During 
2011 >150 000 household contacts were screened for TB and >3 000 
new cases, which would not have been detected through routine 
means, were identified (Lo T, ‘Rapid assessment of intensified 
tuberculosis case finding efforts, Republic of South Africa’ – 
unpublished report by the US Centers for Disease Control to the 
National Department of Health (NDoH), 20 March 2012, available 
on request from Mr Lerole Mametja, Chief Director of the National 
TB Control and Management Cluster). This report also states that 
challenges to the sustained implementation of household-based case 
finding include funding, human resource constraints and lack of 
customised recording and reporting tools. 
IPT
The IPT guidelines for tuberculin skin test (TST)-positive people 
living with HIV were initially incorporated into the ART guidelines. 
Uptake of IPT was poor following introduction of these guidelines, 
largely due to the TST creating a barrier to implementation and 
concerns of generating isoniazid resistance. In 2010, the IPT 
guidelines were revised to remove the TST to facilitate programmatic 
implementation of IPT. The uptake of IPT increased dramatically 
and in 2011 and 2012, >375  000 South Africans living with HIV 
initiated IPT, making SA’s IPT programme one of the largest in the 
world. Despite this, the uptake of IPT among people living with HIV 
in care, including children and pregnant women, remains poor. [9-11] 
The IPT guidelines were re-issued in 2013 as part of the revised 
ART guidelines to recommend at least 36 months of IPT to TST-
positive persons or 6 months of IPT for those whose TST status is 
unknown.[12-15] Stand-alone IPT guidelines are being developed for 
adults and children living with HIV and persons with silicosis. The 
reintroduction of TST into the IPT guidelines may pose a barrier to 
implementation of continuous IPT.
Infection control
People living with HIV and young children are at a high risk of 
exposure to drug-susceptible and -resistant TB when attending 
health facilities for care. Furthermore, healthcare workers are 
also at high risk of acquiring TB nosocomially, which highlights 
the importance of stringent implementation of infection control 
policies in order to reduce TB transmission of drug-susceptible 
and -resistant TB in healthcare facilities and other congregate 
settings.[16] SA introduced a TB infection control programme in 
2007, which included a structural review of healthcare facilities 
and process re-engineering if required. Minimum standards 
for health facilities have been developed by the Council for 
Scientific and Industrial Research. However, the implementation 
of infection control guidelines remains sub-optimal. Healthcare 
facilities should be monitored regularly to ensure consistent 
implementation of infection control guidelines. Infection control 
in other congregate settings, such as correctional service facilities, 
community halls, schools and public transportation (taxis and 
buses), is also required.
ART 
ART reduces the TB risk by 65% overall, and across all CD4+ strata, 
suggesting that earlier ART initiation may contribute to national TB 
control activities.[17] SA has the largest ART programme in the world. 
Although ART substantially reduces the risk of TB among people living 
with HIV, the rate of TB remains four-fold higher than among HIV-
negative persons from the same community.[18] IPT given with ART 
is safe and further reduces the risk of TB by 37%, regardless of TST 
status. [19] SA should therefore scale up the provision of IPT to patients 
on ART. In order for the ART programme to contribute maximally 
to TB control, SA should strive to achieve high coverage of ART and 
consider initiating ART even earlier, including in pregnant women.[15,20] 
MDR-TB 
The number of MDR-TB and XDR-TB cases in SA has increased 
substantially, with 15 419 and 1 596 cases, respectively, diagnosed 
in 2012.[1] The treatment success rate for adult MDR- and XDR-TB 
remains low at 42% and 18%, respectively, for the 2010 cohort. The 
MDR-TB sub-programme has faced many challenges, including 
confirmation of MDR-TB by mycobacterial growth inhibition tube 
(MGIT) liquid culture drug susceptibility testing in only a third of 
patients; high initial loss to follow-up of MDR-TB patients, with 
approximately 40% of patients not initiating appropriate treatment; 
inadequate bed capacity; poor infection control; limited availability 
of appropriate second-line drugs and paediatric formulations; 
and poor adherence to treatment (N Ndjeka, NDoH – personal 
communication). In response to the large burden of MDR-TB, the 
NTP committed >$200 million to the MDR-TB programme; issued 
a series of guidelines for the management of MDR-TB; established 
45, mainly decentralised, MDR- and XDR-TB treatment units, 
with approximately 2  500-bed capacity; and introduced a policy 
framework for the decentralisation and de-institutionalisation of 
drug-resistant TB care and treatment.[21,22] The current standardised 
adult MDR-TB treatment regimen is associated with poor cure 
rates. In order to improve cure rates of MDR-TB, clofazimine has 
been made available, the role of linezolid is being considered, and a 
bedaquiline access programme has been introduced.
Maternal and childhood TB
Childhood TB accounted for 13% of all new TB cases in 2012. [23] 
Treatment outcomes for childhood TB are relatively good, with 
82% of cases successfully treated in 2010. SA enjoys a strong 
political commitment for addressing the challenges of childhood 
TB; a blueprint for action on paediatric and adolescent HIV and TB 
prevention, treatment, care and support has been developed and 
implemented. South Africans have played a leading role in revising 
the 2010 WHO childhood TB treatment guidelines,[24] which 
were adopted in SA. Notable advances in childhood TB include 
changing the age and disease categories for reporting, simplifying 
contact management of TB-exposed children and children living 
with HIV; revision of the Integrated Management of Childhood 
Illness guidelines to include TB screening and management; and 
scaling up prevention of mother-to-child transmission of HIV 
programmes. Many challenges persist for management of childhood 
TB, including the lack of fixed-dose combinations for first-line 
drugs; limited child-friendly second-line drug formulations; poor 
implementation of IPT in HIV-infected child contacts; gaps in 
recording and reporting of childhood TB; weak health systems to 
manage paediatric TB; and poor linkage to care, particularly from 
the hospital to the community.
TUBERCULOSIS CONTROL
247       March 2014, Vol. 104, No. 3 (Suppl 1)
TB/HIV integration
TB/HIV integration requires activities to reduce the burden of TB in 
people living with HIV (discussed above) and to reduce the burden 
of HIV in TB patients. Initiating ART while on TB treatment saves 
lives, regardless of CD4+ count, and among persons with CD4+ counts 
<50  cells/µl, initiating ART soon after initiating TB treatment is 
essential to reduce mortality.[6,25] Decentralisation of ART services 
to primary healthcare clinics and integration with TB services 
have resulted in increasing numbers of TB patients initiating ART. 
In 2012, only 54% of HIV-positive TB patients were initiated on 
ART,[1] highlighting the need to scale up ART for TB patients further 
by scaling up nurse-initiated and managed ART training for all 
professional nurses. 
SA has played a leading role in evaluating strategies to integrate TB 
and HIV services.[26] The PALSA PLUS intervention, which promotes 
integration by providing on-site, case-based, iterative education led 
by a trainer, increased the yield of TB diagnoses.[27] Guidelines for 
integrating TB and HIV services at primary healthcare facilities 
were developed and disseminated in 2010, but TB/HIV integration 
remains poorly implemented and strategies to strengthen integration 
of services, including ART, are required.[28,29] 
Healthcare systems 
The SA government is strengthening the healthcare system through a 
process of primary healthcare re-engineering to balance community-
based preventive services with hospital-based curative services, and 
phased implementation of a National Health Insurance to ensure 
affordability, effectiveness and universal access to quality healthcare 
services, including TB diagnostic and treatment services.[30] These 
initiatives aim to support the implementation of TB control activities 
and promote integration with other primary healthcare services, 
including child and maternal healthcare programmes. Addressing 
the challenge of poor health service management will, however, be 
critical for effective implementation of these government initiatives.
Surveillance and information
The NTP has developed an electronic recording and reporting system 
for drug-susceptible TB (ETR.net) and drug-resistant TB (EDR.
net). There are, however, numerous challenges with the electronic 
recording and reporting systems, including inadequate numbers and 
high turnover of data capturers and poor-quality data entry; linking 
between these two systems; ensuring that hospital-diagnosed cases 
are captured adequately; multiple programme registers and repeated 
data entry at facility level; and lack of a unique health identifier to 
track patients who move between districts and across programmes. 
Novel and sustainable solutions, such as the use of mobile phones 
and tablets to collect data in the field and in facilities, are required to 
strengthen the quality and use of data as well as patient management.
The performance of the NTP is routinely monitored by drug 
resistance and TB prevalence surveys and independent programme 
reviews. The NTP is currently conducting a national drug resistance 
survey, the first national TB prevalence survey is planned, and an 
independent review of the NTP has recently been completed. The 
NTP is also currently implementing the WHO TB Surveillance 
Checklist to assess the effectiveness of the various TB surveillance 
systems in estimating the burden of TB. 
Key populations
TB has been a major health threat in the SA mining industry since 
its inception in the late 1800s. SA goldminers have one of the highest 
TB incidence rates in the world, currently estimated at 3 000/100 000 
population.[14] To address the TB epidemic in the mines, the SA 
Minister of Health, Dr Aaron Motsoaledi, along with the ministers 
of health of Lesotho and Swaziland, spearheaded the development of 
a Southern African Development Community declaration signed by 
the heads of state that provides a framework for addressing TB in the 
mines at a regional level. This constitutes the first ever comprehensive 
multidisciplinary regional response to TB in the mines.
TB is a major health problem in SA prisons due to overcrowding. 
The prevalence of undiagnosed active TB is high (2.4%),[31] and 
requires effective case-finding strategies linked to early treatment 
initiation to ensure cure. The NDoH and the Department of 
Correctional Services have issued TB and HIV guidelines to ensure 
effective control of TB in prisons. Implementation and monitoring 
and evaluation of these guidelines will be critically important. 
Strategies to achieve the NSP targets
Additional strategies are required to meet the NSP and Stop TB 
partnership targets. Mathematical modelling suggests that in addition 
to doing the basics better, scaling up ART and initiating ART earlier, 
scaling up use of Xpert MTB/RIF as a replacement for sputum smear 
microscopy, strengthening targeted case finding in healthcare facilities 
and communities, and introducing and scaling up continuous IPT will 
have a substantial impact on TB control. However, to achieve the NSP 
targets, new effective TB regimens, diagnostics and vaccines need to be 
developed, with consideration of adults and children living with HIV.[32]
Conclusion
SA has made notable progress in improving TB control, but the 
burden of TB remains enormous. This situation can be reversed. 
Ensuring high, sustained coverage of effective interventions for 
TB and HIV, including in children and special populations, will 
substantially reduce the burden of TB and result in the NSP targets 
being met. New drugs, diagnostics and vaccines are required to 
accelerate progress towards TB elimination. 
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